Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1347858/000155837021002771/xxii-20201231x10k.htm
January 2023
November 2022
November 2022
November 2022
September 2022
September 2022
August 2022
July 2022
June 2022
June 2022
Exhibit 99.1
22nd Century Group Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2020
Key Business and Financial Highlights
● | 22nd Century has a tremendous global commercial opportunity in the more than $800 billion markets across the tobacco and hemp/cannabis industry. |
● | Securing Modified Risk Tobacco Product (MRTP) authorization for VLN® remains 22nd Century’s number one priority. The Company is highly confident that the FDA is in the final stages of the review process related to its application. |
● | 22nd Century is fully prepared and eager to launch VLN® King and VLN® Menthol King within 90 days of receiving MRTP designation. MRTP designation is a catalyst for the VLN® brand and tobacco franchise via partnerships and licensing agreements in the U.S. and internationally. |
● | 22nd Century believes that recent political changes will likely be highly favorable to its business prospects from a policy priority and regulatory standpoint. The Company believes that, under the new administration, the FDA will now be re-energized in implementing its ground-breaking Comprehensive Plan for Tobacco and Nicotine Regulation, in particular the Agency’s plan to cap the amount of nicotine in combustible cigarettes to a “minimally or non-addictive” level. |
● | The Company has now secured four out of the five key partnerships needed to maximize each component in the upstream segment of the hemp/cannabis value chain. The partnerships will enable 22nd Century to accelerate the new development of valuable, commercial hemp/cannabis lines and intellectual property to market in two years while it monetizes a portion of the Company’s current portfolio of intellectual property (IP) from its previous license agreement with Anandia Laboratories. 22nd Century is also in final discussions with top-tier plant breeders that will be announced soon. |
● | Net sales revenue of $7.3 million for the fourth quarter was consistent over the prior-year period and improved by 8.8% to $28.1 million for the full-year. |
● | Gross profit for the fourth quarter improved by $364 thousand and by $1.4 million for the full-year; gross profit margin improved by 500 basis points for both periods. |
● | Net loss increased by $207 thousand for the fourth quarter. For the full-year, net loss improved by $6.8 million. |
● | Adjusted EBITDA was unfavorable by $1.3 million for the fourth quarter. For the full-year Adjusted EBITDA improved by $1.8 million. |
● | The Company’s balance sheet is well funded with $22.3 million at the end of full-year 2020. Additional cash of $11.8 million received from warrants exercised in February and March 2021 will provide the Company with additional runway to fuel current operations, strategy, and growth initiatives. 22nd Century does not have any outstanding warrants following these transactions. |
Note: All financials referenced in this release are in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) and comparisons in this release are to the same period in the prior year unless otherwise noted.
WILLIAMSVILLE, N.Y., March 11, 2021 (Globe Newswire) — 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that the Company filed its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission. The Company will provide a business update for investors on a live audio webcast to be held today at 8:00 a.m. ET.
James A. Mish, chief executive officer of 22nd Century Group, together with Michael Zercher, president and chief operating officer, and John Franzino, chief financial officer, will host the webcast. Interested parties are invited to participate by visiting the Events section on the Company’s Investor Relations website at www.xxiicentury.com/investors/events. Following prepared remarks, the Company will host a Q&A session during which management will accept questions from industry analysts. Investors, shareholders, and members of the media will also have the opportunity to submit their questions through the interactive webcast.
“Since joining 22nd Century Group in June, we have communicated our strategic plan and go forth strategy. Our stock price has increased significantly since reporting third quarter earnings demonstrating our commitment to our shareholders,” said James A. Mish, chief executive officer of 22nd Century Group. “As we look to 2021, we see tremendous commercial opportunity for our tobacco and hemp/cannabis franchises. Our focus remains on our primary mission: to reduce the harm caused by smoking. Once we secure MRTP designation, we will capitalize on our VLN® brand and begin to build our tobacco franchise through licensing and partnership opportunities in the U.S. and internationally. We have made significant progress in our hemp/cannabis research and look forward to monetizing a portion of our hemp/cannabis IP this year. With the majority of our hemp/cannabis operational partnerships now in place, we believe we will be able to commercialize our new disruptive, commercially valuable hemp/cannabis plants in development in two years.”
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1347858/000155837021002771/xxii-20201231x10k.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by 22Nd Century Group, Inc..
22Nd Century Group, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:
Rating
Learn More![]()
The decrease was primarily due to amortization expense on a lower patent base which resulted from one-time impairment charges as described in the "Impairment expense" section above.
The increase in cash used for working capital components was primarily due to an increase in pre-paid D&O insurance, which is described further in Note 8 to our consolidated financial statements, and an increase in accounts receivable due to timing of collections.
Realized gain (loss) on short-term investment securities The realized gain on short-term investment securities for the year ended December 31, 2020 was $5, a decrease of $216 from the gain of $221 realized for the year ended December 31, 2019.
Under the new administration, we believe that the FDA will refocus on implementing its ground-breaking Comprehensive Plan for Tobacco and Nicotine Regulation, in particular the agency's plan to cap the amount of nicotine in combustible cigarettes to a "minimally or non-addictive" level.
Amounts in thousands, except for share and per-share data Revenue - Sale of products, net The increase in sales revenue for the year ended December 31, 2020, compared to the year ended December 31, 2019, was primarily the result of an increase in sales revenue of contract manufactured cigarettes.
Personnel expense decreased by $1,285...Read more
We will maintain diligent financial...Read more
In addition, cash flows decreased...Read more
Additionally, license and contract costs...Read more
During 2020, the increase in...Read more
Net cash provided by (used...Read more
He has an outstanding track...Read more
Interest expense for the year...Read more
The cost of such growing...Read more
These increased cash inflows were...Read more
Net cash provided by (used...Read more
Costs of goods sold -...Read more
Research and development expense ?...Read more
We have deployed this incremental...Read more
2020 also included cash interest...Read more
Net loss ? The decrease...Read more
The increase in cigarette sales...Read more
Research and development expense-MRTP ?...Read more
Our investment in Panacea includes...Read more
Impairment of Long-Lived Assets -...Read more
Mr. Mish brings extensive global...Read more
Dr. Koganov is recognized as...Read more
We anticipate a phased rollout...Read more
We believe that an equally...Read more
Ms. Sullivan is also currently...Read more
Filtered cigar sales revenue increased...Read more
We believe that recent political...Read more
Net sales revenue of $7.3...Read more
Our intangible assets subject to...Read more
These contacts, once finalized and...Read more
Interest expense ? Interest expense...Read more
Gross profit for the fourth...Read more
The realized gain on short-term...Read more
Unrealized (loss) gain on investments...Read more
In addition to our ongoing...Read more
Her experience includes the development...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
22Nd Century Group, Inc. provided additional information to their SEC Filing as exhibits
Ticker: XXII
CIK: 1347858
Form Type: 10-K Annual Report
Accession Number: 0001558370-21-002771
Submitted to the SEC: Thu Mar 11 2021 8:36:14 AM EST
Accepted by the SEC: Thu Mar 11 2021
Period: Thursday, December 31, 2020
Industry: Cigarettes